RBC Capital analyst Luca Issi maintained a Hold rating on RegenXBio (NASDAQ:RGNX) on Thursday, setting a price target of $50, which is approximately 54.04% above the present share price of $32.46.
Issi expects RegenXBio to post earnings per share (EPS) of -$1.24 for the second quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Moderate Buy rating of shares in RegenXBio, with an average price target of $55.2.
The analysts price targets range from a high of $65 to a low of $40.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $21.45 million and a net profit of -$53.65 million. The company's market cap is $1.38 billion.
According to TipRanks.com, RBC Capital analyst Luca Issi is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -21.6% and a 10.53% success rate.
REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.